Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Prior treatment

• Any previous therapy for current lung cancer, including chemotherapy or radiation therapy
• Concomitant participation in another therapeutic clinical trial.

Other illness

• Evidence of stage IV NSCLC (metastatic disease).
• Active autoimmune diseases or history of autoimmune diseases that may recur

Lab values

• Previous treatment with an antibody or drug against the immune checkpoint pathway, including but not limited to, therapeutic anti-cytotoxic T-lymphocyte antigen-4-associated antibodies (anti-CTLA-4), anti-PD-1 and anti-PD-L1.

Other

• Histology of large cell neuroendocrine carcinoma (LCNEC).
• Never smoking patients.
• Pregnancy or breastfeeding.

• Histologically confirmed stage III disease.
• Age ≥ 18 years.
• Written informed consent
• PD-L1 TPS ≥ 1% according to local testing.
• No evidence of EGFR mutations or ALK or ROS1 or RET rearrangements by local testing.
• Mandatory baseline multidisciplinary assessment to confirm suitability of patient to local treatment with curative intent.
• Pulmonary function tests within 6 months of the planned resection.
• At least 1 measurable lesion as defined by RECIST v1.1.
• ECOG Performance Status ≤ 1.
• Eligibility to receive a platinum doublet chemotherapy regimen.
• Adequate organ function as indicated by the following laboratory values obtained ≤ 14 days before the first dose of study drug